M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors BioPharma DiveThe Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioPharma Dive The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer. M&A / DealsOncologyRead full story Post navigation Previous: RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degradersNext: Bayer wins MHRA approval for Kerendia in heart failure Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
